Journal Mobile Options
Table of Contents
Vol. 15, No. 3, 2003
Issue release date: February 2003
Dement Geriatr Cogn Disord 2003;15:126–131
(DOI:10.1159/000068483)

Neuropsychological Profile of Patients with Parkinson’s Disease without Dementia

Janvin C. · Aarsland D. · Larsen J.P. · Hugdahl K.
aSection of Geriatric Psychiatry, Rogaland Psychiatric Hospital, and bDepartment of Neurology, Rogaland Central Hospital, Stavanger; cDepartment of Biological and Medical Psychology, University of Bergen, Norway

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Cognitive deficits are often associated with Parkinson’s disease (PD), although their prevalence in PD patients without dementia is still unknown. In order to describe the neuropsychological profile of PD patients without dementia, a sample of 103 PD patients was compared with a control group consisting of 38 healthy elderly subjects. Psychometric assessment consisted of the Mini Mental State Examination, the Dementia Rating Scale and a battery of neuropsychological tests. The Beck Depression Inventory was used to assess depression in PD patients. Dementia was diagnosed in 27 patients. Among non-demented subjects, 34 (45%) had no cognitive impairment and 42 (55%) had a mild cognitive impairment. Subjects with mild cognitive impairment were older, had a later onset of the disease, and more severe motor symptoms than cognitively intact subjects. Identification of mild cognitive impairment is important, since these symptoms are important for patient management and may also facilitate to determine prognosis.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Tandberg E, Larsen JP, Nessler EG, Riise T, Aarli JA: The epidemiology of Parkinson’s disease in the county of Rogaland, Norway. Mov Disord 1995;10:541–549.
  2. Aarsland D, Tandberg E, Larsen JP, Cummings JL: Frequency of dementia in Parkinson’s disease. Arch Neurol 1996;53:538–542.
  3. McFadden L, Mohr E, Sampson M, Mendis T, Grimes D: A profile analysis of demented and nondemented Parkinson’s disease patients. Adv Neurol 1996;69:339–341.
  4. Levin BE, Llabre MM, Weiner WJ: Cognitive impairments associated with early Parkinson’s disease. Neurology 1989;39:557–561.
  5. Lees AJ, Smith E: Cognitive deficits in the early stages of Parkinson’s disease. Brain 1983;106:257–270.

    External Resources

  6. Hietanen M, Teravainen H: Cognitive performance in early Parkinson’s disease. Acta Neurol Scand 1986;73:151–159.
  7. Marsden CD: The mysterious motor function of the basal ganglia. The Robert Wartenberg Lecture. Neurology 1982;32:514–539.
  8. Piccirilli M, D’Alessandro P, Finali G, Piccinin GL, Agostini L: Frontal lobe dysfunction in Parkinson’s disease: Prognostic value for dementia? Eur Neurol 1989;29:71–76.
  9. Owen AM, Robbins TW: Comparative neuropsychology of parkinsonian syndromes; in Wolters EC, Scheltens P (eds): Mental Dysfunction in Parkinson’s Disease. Dordrecht, ICG Printing, 1993, pp 221–242.
  10. Aarsland D, Larsen JP, Karlsen K, Lim NG, Tandberg E: Mental symptoms in Parkinson’s disease are important contributors to caregiver distress. Int J Geriatr Psychiatry 1999;14:866–874.
  11. Larsen JP, Dupon E, Tandberg E: The clinical diagnosis of Parkinson’s disease: Proposal of diagnostic subgroups classified at different levels of confidence. Acta Neurol Scand 1994;84:242–251.
  12. Fahn S, Elton RL: Members of the UPDRS Development Committee. Unified Parkinson’s Disease Rating Scale; in Fahn S, Marsden CD, Calne DB, Lieberman A (eds): Recent Development in Parkinson’s Disease. Florham Park, Macmillan Health Care Information, 1987, pp 153–163.
  13. Hoehn MH, Yahr MD: Parkinsonism: Onset, progression, and mortality. Neurology 1967;17:427–442.
  14. Diagnostic and Statistical Manual of Mental Disorders, ed 3, revised. Washington, American Psychiatric Association, 1987.
  15. Folstein MF, Folstein SE, McHugh PR: Mini Mental State: A practical method for grading the mental state of patients for the clinician. J Psychiatry Res 1975;12:189–198.
  16. Mattis S: Dementia Rating Scale; in Bellak L, Karasu TB (eds): Geriatric Psychiatry. A Handbook for Psychiatrists and Primary Care Physicians. New York, Grune & Stratton, 1976, pp 108–121.
  17. Paolo AM, Troster AI, Sander LG, Hubble JP, Koller WC: Differentiation of the dementias of Alzheimer’s and Parkinson’s disease with the Dementia Rating Scale. J Geriatr Psychiatry Neurol 1995;8:184–188.
  18. Salmon DP, Kwon-on-Yuen PF, Heindel WC, Butters N, Leon JT: Differentiation of Alzheimer’s disease and Huntington’s disease with the Dementia Rating Scale. Arch Neurol 1989;46:1204–1208.
  19. Benton AL: The revised visual retention test, ed 4. New York, Psychological Corporation, 1974.
  20. Benton AL, Varney NR, Hamsher KD: Visuospatial judgment: A clinical test. Arch Neurol 1978;35:364–367.
  21. Golden JC: Stroop Color and Word Test. Chicago, Stoelting, 1978.
  22. Beck AT: Beck depression inventory. San Antonio, Psychological Corporation, 1978.
  23. Aarsland D, Larsen JP, Cummings JL, Laake K: Prevalence and clinical correlates of psychotic symptoms in Parkinson’s disease. Arch Neurol 1999;56:595–601.
  24. Dubois B, Pillon B, Sternic N, Lhermitte F, Agid Y: Age-induced cognitive disturbance in Parkinson’s disease. Neurology 1990;40:38–41.
  25. Hughes TA, Ross HF, Musa S, Bhattacherjee S, Nathan RN, Mindham RH, Spokes EG: A 10-year study of the incidence of and factors predicting dementia in Parkinson’s disease. Neurology 2000;54:1596–1602.
  26. Aarsland D, Andersen K, Larsen JP, Lolk A, Nielsen H, Kragh-Sørensen P: Risk of dementia in Parkinson’s disease. A community-based, prospective study. Neurology 2001;56:730–736.
  27. Troster AI, Stalp LD, Paolo AM, Fields JA, Koller WC: Neuropsychological impairment in Parkinson’s disease with and without depression. Arch Neurol 1995;52:1164–1169.
  28. Tomer R, Levin BE, Weiner WJ: Side of onset of motor symptoms influences cognition in Parkinson’s disease. Ann Neurol 1993;34:579–584.
  29. Levin BE, Katzen HL: Early cognitive changes and nondementing behavioral abnormalities in Parkinson’s disease; in Weiner WJ, Lang AE (eds): Behavioral Neurology of Movement Disorders. Adv Neurol. New York, Raven, 1995, vol 65, pp 85–95.
  30. Biggins CA, Boyd JL, Harrop FM, Madeley P, Mindham RH, Randall JI, Spokes EG: A controlled, longitudinal study of dementia in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1992;55:566–571.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50